Company / EPS (Basic)
Denali Therapeutics Inc. EPS (Basic) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$1.06
FY2025
5-year range
-$2.60 / $0.65
FY2021-FY2025
Trend
+59.2%
vs FY2024
Sector context
#87 of 208
Health Care
What the data says
At $-1.06, Denali Therapeutics Inc.'s eps (basic) ranks #87 of 208 in the Health Care sector. EPS (Basic) returned to growth in FY2025 after 2 years of decline, reaching $-1.06.
Based on SEC 10-K filings.
-1.06 in FY2025.
Improved from $-2.39 to $-1.06 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#87 of 208 in Health CareTop 42% of 208This company -$1.06 Sector average -$0.96
▼
-10.1% below sector average
Key checks
Key Insights
- In FY2025, eps (basic) increased 59.2% year-over-year.
- Ranks #87 out of 208 companies in the Health Care sector.
- Peak eps (basic) was recorded in FY2022.
- Lowest eps (basic) in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.06 | +59.2% |
| FY2024 | -$2.60 | -8.8% |
| FY2023 | -$2.39 | -467.7% |
| FY2022 | $0.65 | +131.4% |
| FY2021 | -$2.07 | -430.8% |
| FY2020 | -$0.39 | - |
| FY2019 | - | - |
| FY2018 | -$0.26 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026